The programs in our portfolio are rooted in our deep mechanistic understanding of immunobiology leading to our translational focus in the disease areas of immunology, inflammation, immuno-oncology and fibrosis. Our core portfolio currently consists of four programs at various stages of clinical and preclinical development and have the potential to meaningfully improve the lives of patients who are suffering from disease. The Gossamer strategy includes leveraging an asset-rich in-licensing environment in our core areas of focus, using our in-house expertise to maximize parallel development where target biology is relevant, and driving internal research efforts on new innovative biology in areas of high unmet need.
DP2 antagonist – moderate to severe eosinophilic asthma. Phase 2b ongoing.
DP2 antagonist – chronic rhinosinusitis with nasal polyps. Phase 2 planned.
DP2 antagonist – chronic spontaneous urticaria. Phase 2 planned.
PDGF receptor kinase inhibitor - pulmonary arterial hypertension. Phase 1 ongoing.
HIF-1a stabilizer – Inflammatory Bowel Disease. Phase 1 ongoing.
CD11b agonist. Preclinical program.
*Targets to be disclosed